215 related articles for article (PubMed ID: 15093960)
1. Increased inositol-monophosphatase activity by lithium treatment in bipolar patients.
Kaya N; Resmi H; Ozerdem A; Guner G; Tunca Z
Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):521-7. PubMed ID: 15093960
[TBL] [Abstract][Full Text] [Related]
2. Inositol monophosphatase--a putative target for Li+ in the treatment of bipolar disorder.
Atack JR; Broughton HB; Pollack SJ
Trends Neurosci; 1995 Aug; 18(8):343-9. PubMed ID: 7482796
[TBL] [Abstract][Full Text] [Related]
3. Regional changes in rat brain inositol monophosphatase 1 (IMPase 1) activity with chronic lithium treatment.
Parthasarathy LK; Seelan RS; Wilson MA; Vadnal RE; Parthasarathy RN
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb; 27(1):55-60. PubMed ID: 12551726
[TBL] [Abstract][Full Text] [Related]
4. Myo-inositol monophosphatase: diverse effects of lithium, carbamazepine, and valproate.
Vadnal R; Parthasarathy R
Neuropsychopharmacology; 1995 Jul; 12(4):277-85. PubMed ID: 7576004
[TBL] [Abstract][Full Text] [Related]
5. Interaction of calbindin D28k and inositol monophosphatase in human postmortem cortex: possible implications for bipolar disorder.
Shamir A; Elhadad N; Belmaker RH; Agam G
Bipolar Disord; 2005 Feb; 7(1):42-8. PubMed ID: 15654931
[TBL] [Abstract][Full Text] [Related]
6. [Predictors of prophylactic response to lithium].
Rohayem J; Baylé JF; Richa S
Encephale; 2008 Sep; 34(4):394-9. PubMed ID: 18922242
[TBL] [Abstract][Full Text] [Related]
7. Inositol-1-phosphatase in red blood cells of manic-depressive patients before and during treatment with lithium.
Moscovich DG; Belmaker RH; Agam G; Livne A
Biol Psychiatry; 1990 Mar; 27(5):552-5. PubMed ID: 2155674
[No Abstract] [Full Text] [Related]
8. How does lithium work on manic depression? Clinical and psychological correlates of the inositol theory.
Belmaker RH; Bersudsky Y; Agam G; Levine J; Kofman O
Annu Rev Med; 1996; 47():47-56. PubMed ID: 8712796
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of inositol monophosphatase (IMPase) at the calbindin-D28k binding site: molecular and behavioral aspects.
Levi I; Eskira Y; Eisenstein M; Gilon C; Hoffman A; Tal-Gan Y; Fanous J; Bersudsky Y; Belmaker RH; Agam G; Almog O
Eur Neuropsychopharmacol; 2013 Dec; 23(12):1806-15. PubMed ID: 23619164
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid inositol monophosphatase: elevated activity in depression and neuroleptic-treated schizophrenia.
Atack JR; Levine J; Belmaker RH
Biol Psychiatry; 1998 Sep; 44(6):433-7. PubMed ID: 9777174
[TBL] [Abstract][Full Text] [Related]
11. Stereochemistry at phosphorus of the reaction catalyzed by myo-inositol monophosphatase.
Fauroux CM; Lee M; Cullis PM; Douglas KT; Gore MG; Freeman S
J Med Chem; 2002 Mar; 45(6):1363-73. PubMed ID: 11882005
[TBL] [Abstract][Full Text] [Related]
12. Tryptophan depletion in recently manic patients treated with lithium.
Cassidy F; Murry E; Carroll BJ
Biol Psychiatry; 1998 Feb; 43(3):230-2. PubMed ID: 9494705
[TBL] [Abstract][Full Text] [Related]
13. Inositol monophosphatase, the putative therapeutic target for lithium.
Atack JR
Brain Res Brain Res Rev; 1996 Aug; 22(2):183-90. PubMed ID: 8883919
[TBL] [Abstract][Full Text] [Related]
14. Biological predictors of lithium response in bipolar disorder.
Ikeda A; Kato T
Psychiatry Clin Neurosci; 2003 Jun; 57(3):243-50. PubMed ID: 12753562
[TBL] [Abstract][Full Text] [Related]
15. Effects of chronic lithium treatment on retinal electrophysiologic function.
Lam RW; Allain S; Sullivan K; Beattie CW; Remick RA; Zis AP
Biol Psychiatry; 1997 Mar; 41(6):737-42. PubMed ID: 9066998
[TBL] [Abstract][Full Text] [Related]
16. Inositol-deficient food augments a behavioral effect of long-term lithium treatment mediated by inositol monophosphatase inhibition: an animal model with relevance for bipolar disorder.
Shtein L; Agam G; Belmaker RH; Bersudsky Y
J Clin Psychopharmacol; 2015 Apr; 35(2):175-7. PubMed ID: 25679134
[TBL] [Abstract][Full Text] [Related]
17. Lithium decreases VEGF mRNA expression in leukocytes of healthy subjects and patients with bipolar disorder.
Kikuchi K; Iga J; Tayoshi S; Nakataki M; Watanabe S; Numata S; Ohmori T
Hum Psychopharmacol; 2011; 26(4-5):358-63. PubMed ID: 21721043
[TBL] [Abstract][Full Text] [Related]
18. Examination of IMPA1 and IMPA2 genes in manic-depressive patients: association between IMPA2 promoter polymorphisms and bipolar disorder.
Sjøholt G; Ebstein RP; Lie RT; Berle JØ; Mallet J; Deleuze JF; Levinson DF; Laurent C; Mujahed M; Bannoura I; Murad I; Molven A; Steen VM
Mol Psychiatry; 2004 Jun; 9(6):621-9. PubMed ID: 14699425
[TBL] [Abstract][Full Text] [Related]
19. Behavioral analyses of transgenic mice harboring bipolar disorder candidate genes, IMPA1 and IMPA2.
Ohnishi T; Watanabe A; Ohba H; Iwayama Y; Maekawa M; Yoshikawa T
Neurosci Res; 2010 May; 67(1):86-94. PubMed ID: 20153384
[TBL] [Abstract][Full Text] [Related]
20. Lithium safety in the prophylaxis of bipolar disorders: a study with plasma levels.
Mauri MC; Laini V; Scalvini ME; Volonteri LS; Ferrari MS; Panza G
Eur Rev Med Pharmacol Sci; 1999; 3(2):63-9. PubMed ID: 10827806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
